title: Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: a clinical overview.
abstract: Affecting up to 1% of the global population, schizophrenia is a chronic, disabling psychiatric disorder that has profound effects on patients, families, and caretakers due to its tremendous personal, social, and economic burdens. Schizophrenia commonly presents during late adolescence and early adulthood, and although its onset may be abrupt, the majority of patients experience a slow and gradual development of various clinical signs and symptoms. In addition to psychotic symptoms that may alter one's perception, thoughts, affect, and behavior, schizophrenia is associated with increased morbidity and mortality, reduced life expectancy, and higher risks of homelessness and unemployment. Although much research has been conducted on schizophrenia, the exact etiology of the disease remains unclear and is likely multifactorial, and evidence has suggested that neuroanatomical alterations and neurotransmitter abnormalities contribute to the disease's pathophysiology. It is essential to remember that schizophrenia is a chronic disease that requires long-term treatment. While there are currently no definitive diagnostic tests for schizophrenia, the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria should be used to guide proper diagnosis and identification. Further research and an improved understanding of the pathophysiological basis of schizophrenia may drive more effective treatment options and improved patient outcomes for this complex and challenging disease.
authors.affiliation: dcj2113@columbia.edu.
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Javitt
mesh_terms: D006801:Humans; D055118:Medication Adherence; D061214:Patient Safety; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology